Protagonist Therapeutics (PTGX) Amortization of Deferred Charges (2021 - 2024)
Protagonist Therapeutics (PTGX) posted Amortization of Deferred Charges of $418000.0 for Q4 2024, little changed sequentially from $416000.0 in Q3 2024, and down 28.42% YoY from $584000.0 in Q1 2024.
Protagonist Therapeutics (PTGX) Amortization of Deferred Charges (2021 - 2024) Analysis & Trends
Protagonist Therapeutics has reported Amortization of Deferred Charges for 4 years, with the latest figure at $418000.0 in Q4 2024.
- Quarterly Amortization of Deferred Charges fell 28.42% year-over-year to $418000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.1 million (down 11.39% YoY) and the FY2024 annual result came in at $2.1 million, down 11.39% from the prior year.
- Amortization of Deferred Charges was little changed at $418000.0 in Q4 2024 per PTGX's latest filing, from $416000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $651000.0 in Q2 2024 and troughed at $416000.0 in Q3 2024.
- A 4-year average of $543812.5 and a median of $584000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2022 and 2024: Amortization of Deferred Charges surged 31.83% in 2022, then retreated 28.64% in 2024.
- Over 4 years, Amortization of Deferred Charges stood at $584000.0 in 2021, then changed by 0.0% to $584000.0 in 2022, then changed by 0.0% to $584000.0 in 2023, then dropped by 28.42% to $418000.0 in 2024.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $418000.0, $416000.0, and $651000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 418,000.00 |
| Dec 31, 2024 | 418,000.00 |
| Sep 30, 2024 | 416,000.00 |
| Sep 30, 2024 | 416,000.00 |
| Jun 30, 2024 | 651,000.00 |
| Jun 30, 2024 | 651,000.00 |
| Mar 31, 2024 | 584,000.00 |
| Mar 31, 2024 | 584,000.00 |
| Dec 31, 2023 | 584,000.00 |
| Dec 31, 2023 | 584,000.00 |
| Sep 30, 2023 | 583,000.00 |
| Sep 30, 2023 | 583,000.00 |
| Jun 30, 2023 | 584,000.00 |
| Jun 30, 2023 | 584,000.00 |
| Mar 31, 2023 | 584,000.00 |
| Mar 31, 2023 | 584,000.00 |
| Dec 31, 2022 | 584,000.00 |
| Dec 31, 2022 | 584,000.00 |
| Sep 30, 2022 | 583,000.00 |
| Sep 30, 2022 | 583,000.00 |